Eversince the advent of corona virus’ new strain get detected in the United Kingdom, AIIMS Director Randeep Guleria stated that the vaccines in the trial phase should also be considered as effective against the infection. According to the sources of “The Reader’s Time”, while speaking to a leading portal Guleria, a member of the national task force on COVID-19 management asked people not to panic as the ‘ Corona Virus has undergone several mutations, an average of two per month’.
Randeep further mentioned that “ The mutations have not led to any change in symptoms and treatment strategy. The vaccines which are still in the trail phase and up for exigency authorisation should also be effective against the new UK strain.”
However, the AIIMS Director added that UK strain was more infectious,and following this the authorities red-flagged it solely. Earlier at a conference, VK Paul, a top COVID -19 adviser to Prime Minister Narendra Modi, had said that the new more transmissible strain of the corona virus detected in Britain has not yet been found in India.
“It is also being said that in these viruses, the transmissibility has increased by 70percent, you can also call them super spreader in a way but it does not increase the propensity of death, hospitalisation and severity of the disease. What is affected is tendency to affect more people that by itself is a cause of concern” he said.
On 19th December, British Prime Minister Boris Johnson warned of the mutant virus strain which has quickly spread across London and the southeast of England. By the ending week of December, the new variant accounted for 62% in London, 59% in Eastern England and 43% in the South East. Less than 24hours after the annoucent, several countries , including India banned flights to and fro from the United Kingdom.